LGM
UNCY icon

Logos Global Management’s Unicycive Therapeutics UNCY Stock Holding History

Logos Global Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Hold
473,563
– – 0.1% 59
2026
Q1 		$3.12M Hold
473,563
– – 0.16% 58
2025
Q4 		$2.73M Hold
473,563
– – 0.17% 61
2025
Q3 		$2.06M Buy
473,563
+1
+0% +$4 0.19% 53
2025
Q2 		$2.26M Sell
473,562
-34,331
-7% -$212K 0.25% 49
2025
Q1 		$2.92M Hold
507,893
– – 0.52% 30
2024
Q4 		$4.03M Hold
507,893
– – 0.47% 38
2024
Q3 		$2.07M Buy
507,893
+160,900
+46% +$646K 0.22% 50
2024
Q2 		$1.74M Hold
346,993
– – 0.14% 54
2024
Q1 		$3.01M Buy
+346,993
New +$4.21M 0.24% 50

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Logos Global Management's UNCY Position: Q2 2026 in Review

Logos Global Management held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 473,563 shares worth $2.22M. The position accounts for 0.1% of the portfolio, ranked #59.

Logos Global Management first reported a position in UNCY in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.03M in Q4 2024. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Logos Global Management held 473,563 shares of Unicycive Therapeutics worth $2.22M as of Q2 2026.
  • Logos Global Management left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up 0.1% of Logos Global Management's portfolio in Q2 2026, its #59 holding.
  • Logos Global Management first reported a position in Unicycive Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Logos Global Management's Unicycive Therapeutics position peaked at $4.03M in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.